Profound Medical Corp. (TSX:PRN)
Canada flag Canada · Delayed Price · Currency is CAD
8.71
-0.06 (-0.68%)
Feb 9, 2026, 4:00 PM EST

Profound Medical Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-39.34-27.82-28.32-28.67-30.7-21.62
Depreciation & Amortization
0.690.940.9311.010.81
Other Amortization
---0.60.870.73
Asset Writedown & Restructuring Costs
---2.52--
Stock-Based Compensation
4.552.583.424.247.213.02
Provision & Write-off of Bad Debts
-0.07-0.310.15---
Other Operating Activities
0.160.560.680.130.131.13
Change in Accounts Receivable
-1.50.19-0.96-1.422-4.03
Change in Inventory
-2.110.660.35-1.86-2.49-2.14
Change in Accounts Payable
0.980.821.35-0.57-0.360.1
Change in Unearned Revenue
-0.91-0.950.19---
Change in Income Taxes
0.04--0.30.31-0.010
Change in Other Net Operating Assets
0.130.03-0.16-2.09-0.011.25
Operating Cash Flow
-37.52-23.45-22.61-25.8-22.36-20.57
Capital Expenditures
-----0.03-
Sale (Purchase) of Intangibles
-----0.56-0.35
Investing Cash Flow
-----0.59-0.35
Long-Term Debt Issued
---7.27--
Total Debt Issued
---7.27--
Long-Term Debt Repaid
--2.56-0.91-0.36-0.39-9.61
Total Debt Repaid
-1.03-2.56-0.91-0.36-0.39-9.61
Net Debt Issued (Repaid)
-1.03-2.56-0.916.92-0.39-9.61
Issuance of Common Stock
39.2162.152.670.266.43103.68
Other Financing Activities
-3.04-4.9--0.15-0.1-6.64
Financing Cash Flow
35.1554.71.767.035.9587.43
Foreign Exchange Rate Adjustments
0.08-2.540.55-1.870.242.6
Net Cash Flow
-2.328.7-20.3-20.64-16.7669.11
Free Cash Flow
-37.52-23.45-22.61-25.8-22.39-20.57
Free Cash Flow Margin
-262.43%-219.60%-314.06%-386.17%-325.80%-281.68%
Free Cash Flow Per Share
-1.29-0.95-1.07-1.24-1.09-1.19
Levered Free Cash Flow
-23.12-15.05-13.15-18.78-7.22-13.31
Unlevered Free Cash Flow
-23.12-15.05-13.15-18.68-7.18-12.97
Change in Working Capital
-3.510.590.54-5.63-0.88-4.64
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.